Published in Catheter Cardiovasc Interv on August 11, 2014
What Could be Changed in the 2012 Taiwan ST-Segment Elevation Myocardial Infarction Guideline? Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.88
First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry). Arq Bras Cardiol (2016) 0.75
Drug eluting stents in primary PCI: ready for prime-time? Catheter Cardiovasc Interv (2014) 0.75
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 8.13
Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction. Circ Res (2011) 5.87
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
"False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA (2007) 2.89
Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv (2010) 2.88
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88
Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA (2006) 2.83
ST-elevation myocardial infarction diagnosed after hospital admission. Circulation (2014) 2.83
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (2009) 2.82
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
Comparison of circadian rhythm patterns in Tako-tsubo cardiomyopathy versus ST-segment elevation myocardial infarction. Am J Cardiol (2012) 2.66
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. J Am Coll Cardiol (2005) 2.19
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation (2011) 2.18
Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. Catheter Cardiovasc Interv (2013) 2.02
Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol (2006) 1.96
Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation (2011) 1.95
Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res (2010) 1.84
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med (2009) 1.72
Long-term survival in patients with refractory angina. Eur Heart J (2013) 1.68
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.65
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation (2013) 1.62
Increased prevalence of coronary artery aneurysms among cocaine users. Circulation (2005) 1.60
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2012) 1.59
CD34 expression by hair follicle stem cells is required for skin tumor development in mice. Cancer Res (2007) 1.55
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol (2005) 1.52
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J (2010) 1.52
Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol (2012) 1.51
Causes of delay and associated mortality in patients transferred with ST-segment-elevation myocardial infarction. Circulation (2011) 1.49
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol (2005) 1.47
Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol (2004) 1.47
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J (2011) 1.46
Elevated T-wave alternans predicts nonsustained ventricular tachycardia in association with percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) patients. J Cardiovasc Electrophysiol (2013) 1.46
The prognostic role of mitral regurgitation after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Catheter Cardiovasc Interv (2012) 1.45
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv (2010) 1.45
Increasing survival rate from commotio cordis. Heart Rhythm (2012) 1.45
Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: findings from the HORIZONS-AMI trial. Catheter Cardiovasc Interv (2013) 1.44
Emerging therapies for refractory angina. Minn Med (2008) 1.42
An interactive visualization tool for multi-channel confocal microscopy data in neurobiology research. IEEE Trans Vis Comput Graph (2009) 1.42
Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention (2013) 1.41
Age-related effects of smoking on culprit lesion plaque vulnerability as assessed by grayscale and virtual histology-intravascular ultrasound. Coron Artery Dis (2015) 1.40
Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. Circ Cardiovasc Qual Outcomes (2012) 1.39
Phase I cardiovascular cell therapy clinical trials: Are we running with scissors? Am Heart J (2008) 1.39
Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial. Coron Artery Dis (2015) 1.39
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res (2015) 1.39
Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation (2003) 1.38
Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J Immunol (2007) 1.36
A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J (2011) 1.35
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv (2009) 1.35
Standardized reporting guidelines for studies evaluating risk stratification of emergency department patients with potential acute coronary syndromes. Ann Emerg Med (2004) 1.33
Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med (2002) 1.31
Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial. Prev Med (2002) 1.30
Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther (2012) 1.27
Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol (2005) 1.27
Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. Am Heart J (2010) 1.27
Interactive display of isosurfaces with global illumination. IEEE Trans Vis Comput Graph (2006) 1.25
Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation (2011) 1.25
The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther (2005) 1.22
Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J (2003) 1.21
Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv (2011) 1.16
Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol (2010) 1.16
Growth in percutaneous coronary intervention capacity relative to population and disease prevalence. J Am Heart Assoc (2013) 1.16
Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol (2007) 1.14
Therapeutic hypothermia after out-of-hospital cardiac arrest: evaluation of a regional system to increase access to cooling. Circulation (2011) 1.14
Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. J Am Coll Cardiol (2009) 1.14
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J (2011) 1.13
Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. Circ Res (2014) 1.12
Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol (2009) 1.12
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. Am Heart J (2006) 1.12
One-year survival in patients with acute myocardial infarction and a saphenous vein graft culprit treated with primary angioplasty. Am J Cardiol (2003) 1.11
Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circ Cardiovasc Interv (2011) 1.11